- Home
- SM vs IMVT Comparison
SM vs IMVT Comparison
Compare SM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SM
- IMVT
- Stock Information
- Founded
- SM 1908
- IMVT 2018
- Country
- SM United States
- IMVT United States
- Employees
- SM N/A
- IMVT N/A
- Industry
- SM Oil & Gas Production
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SM Energy
- IMVT Health Care
- Exchange
- SM Nasdaq
- IMVT Nasdaq
- Market Cap
- SM 3.1B
- IMVT 2.7B
- IPO Year
- SM 1992
- IMVT N/A
- Fundamental
- Price
- SM $27.36
- IMVT $15.40
- Analyst Decision
- SM Hold
- IMVT Buy
- Analyst Count
- SM 11
- IMVT 11
- Target Price
- SM $42.44
- IMVT $33.88
- AVG Volume (30 Days)
- SM 1.7M
- IMVT 1.6M
- Earning Date
- SM 10-30-2025
- IMVT 11-06-2025
- Dividend Yield
- SM 2.94%
- IMVT N/A
- EPS Growth
- SM 1.83
- IMVT N/A
- EPS
- SM 7.07
- IMVT N/A
- Revenue
- SM $3,002,621,000.00
- IMVT N/A
- Revenue This Year
- SM $33.13
- IMVT N/A
- Revenue Next Year
- SM N/A
- IMVT N/A
- P/E Ratio
- SM $3.85
- IMVT N/A
- Revenue Growth
- SM 27.02
- IMVT N/A
- 52 Week Low
- SM $19.67
- IMVT $12.72
- 52 Week High
- SM $46.42
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- SM 51.41
- IMVT 46.55
- Support Level
- SM $26.03
- IMVT $16.08
- Resistance Level
- SM $28.65
- IMVT $15.82
- Average True Range (ATR)
- SM 1.07
- IMVT 0.82
- MACD
- SM -0.04
- IMVT -0.05
- Stochastic Oscillator
- SM 41.56
- IMVT 32.29
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.